Business Wire

FourKites Hires Supply Chain Veteran in Europe, Underscoring Significant Growth in International Ocean Visibility

Share

Philippe Salles has been appointed FourKites’ Vice President of Strategic Solutions (Ocean), bringing a wealth of experience to this booming area of the company’s business.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005080/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Philippe Salles has been appointed FourKites’ Vice President of Strategic Solutions (Ocean). (Photo: Business Wire)

“I’m delighted to be joining FourKites,” says Philippe, who brings experience from CMA CGM, INTTRA and maritime research and consultancy firm Drewry. “Visibility has been ocean shippers’ top priority for decades, and today’s real-time visibility platforms have completely changed the game. In addition to its market-leading machine learning-driven platform, FourKites understands that industry mindset and professionalism are as important as the technology itself. We need to provide shippers with a long-term strategic vision for their supply chain to make them resilient and collaborative.”

Philippe is an industry veteran with a detailed understanding of current supply chain issues. In his new role at FourKites, he will work closely with FourKites shippers and carriers to support them as they execute the change management needed to improve end-to-end supply chain visibility. Moreover, he will accelerate time to value for FourKites users by removing operational pain points and maximising the effectiveness of the systems they use.

“Philippe has a rare depth of experience, especially when it comes to evolving some of the traditional areas of ocean shipping with new technology,” says Mathew Elenjickal, FourKites Founder and CEO. “His network, the trust he's built up in the industry and his expertise in supply chain management will be invaluable to our customers as we continue to drive innovation in ocean visibility.”

FourKites sees unprecedented ocean momentum

Salles’ appointment is the latest leap forward in FourKites’ momentum in supply chain visibility for seagoing container traffic. FourKites now tracks 98% of global ocean container traffic across more than 270 lanes and 120 carriers, and covers every container port in North America and all major ports in Europe.

Over the last 12 months, the company has seen:

  • 79% growth in the number of customers using supply chain visibility for international shipments, with a 23% jump in Q1 2022 alone
  • 215% growth in the volume of seagoing freight that it tracks, with a 190% increase in ocean shipments in EMEA
  • 16% growth in the number of ports tracked in EMEA, now totalling coverage of 239 ports in the region and 804 ports globally

In the last quarter, FourKites signed a number of new ocean customers, including Cardinal Health, Arizona Tile, LyondellBasell, McCain Foods, Roehm, Rove Concepts and Yamaha Motors, among many others.

LyondellBasell, to take one example, is a top-10 global chemicals producer with operations around the world. The company has been a FourKites customer since 2018, when it began tracking shipments across all modes of transport in North America. Based on its success to date with the FourKites platform, the company extended its contract with FourKites in Q1 2022 to track multimodal shipments in Europe.

“Global shippers love FourKites’ Dynamic OceanSM platform because it addresses the full spectrum of shipping issues,” says Philippe. “And the company’s proprietary Dynamic ETA® technology provides estimated times of arrival that are 20% to 40% more accurate than carrier-generated figures. That’s important because timing errors can add significantly to costs.”

FourKites’ Dynamic Ocean addresses the full spectrum of ocean shipping issues through advanced document management and collaboration features; state-of-the-art real-time tracking capabilities, including highly accurate predictive ETAs; and comprehensive multimodal visibility from port to door, including the yard, so shippers can identify and manage the root causes of escalating fees.

About FourKites

Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 200 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,000 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Scott Johnston
Director of European PR for FourKites
+31 62 147 8442
scott.johnston@fourkites.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye